• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Talphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 4:10:32 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email
    acrx20250513_8k.htm
    false 0001427925 0001427925 2025-05-14 2025-05-14
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
     
    FORM 8-K
     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): May 14, 2025
     
    TALPHERA, INC.
    (Exact name of registrant as specified in its charter)
     
    Delaware
     
    001-35068
     
    41-2193603
    (State of incorporation)
     
    (Commission File No.)
     
    (IRS Employer Identification No.)
     
     
    1850 Gateway Drive, Suite 175
    San Mateo, CA 94404
    (Address of principal executive offices and zip code)
     
    Registrant’s telephone number, including area code: (650) 216-3500
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
    Securities registered pursuant to Section 12(b) of the Act
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, $0.001 par value
    TLPH
    The Nasdaq Global Market
     
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 2.02         Results of Operations and Financial Condition
     
    On May 14, 2025, Talphera, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2025 and providing a corporate update (the “Release”). A copy of the Release is furnished herewith as Exhibit 99.1.
     
    The information contained in this Item 2.02 and in Exhibit 99.1 shall be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02 and in Exhibit 99.1 shall not be incorporated by reference into any filing under the Securities Act or the Exchange Act made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific reference in such filing.
     
     
    Item 9.01         Financial Statements and Exhibits
     
    Exhibit No.
    Description
    99.1
    Press Release dated May 14, 2025
    104
    Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     
     
    SIGNATURES
     
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: May 14, 2025 TALPHERA, INC.
         
      By: /s/ Raffi Asadorian
        Raffi Asadorian
        Chief Financial Officer
     
     
    Get the next $TLPH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update. "We have enrolled 15 patients in the NEPHRO clinical

    8/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

    SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link

    8/7/25 4:35:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

    Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif., May 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial res

    5/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Rodman & Renshaw initiated coverage on Talphera with a new price target

    Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

    1/28/25 7:17:45 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $125,000 worth of shares (213,310 units at $0.59) and was granted 61,000 shares, increasing direct ownership by 149% to 474,769 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:28:23 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil bought $6,038 worth of shares (5,695 units at $1.06), increasing direct ownership by 18% to 37,695 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    2/26/25 6:52:05 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF EXECUTIVE OFFICER Angotti Vincent J. bought $3,200 worth of shares (5,000 units at $0.64), increasing direct ownership by 2% to 208,066 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    12/6/24 6:05:05 AM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Aslam Shakil covered exercise/tax liability with 4,517 units of Commom Stock, decreasing direct ownership by 9% to 48,178 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    5/21/25 6:57:17 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Aslam Shakil was granted 15,000 units of Commom Stock, increasing direct ownership by 40% to 52,695 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:31:19 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Engineering Officer Dasu Badri N was granted 15,000 shares, increasing direct ownership by 56% to 42,011 units (SEC Form 4)

    4 - TALPHERA, INC. (0001427925) (Issuer)

    4/3/25 4:30:21 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    SEC Filings

    View All

    SEC Form 10-Q filed by Talphera Inc.

    10-Q - TALPHERA, INC. (0001427925) (Filer)

    8/14/25 5:02:57 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TALPHERA, INC. (0001427925) (Filer)

    8/14/25 4:10:55 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - TALPHERA, INC. (0001427925) (Filer)

    6/5/25 5:02:39 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TLPH
    Leadership Updates

    Live Leadership Updates

    View All

    Ascentage Pharma Appoints Ms. Marina S. Bozilenko and Dr. Debra Yu as Independent Non-Executive Directors

    ROCKVILLE, Md. and SUZHOU, China, Nov. 24, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has appointed Ms. Marina S. Bozilenko and Dr. Debra Yu as additional independent non-executive directors of the company with effect from November 25, 2024. "I would like to extend a warm welcome to Ms. Marina S. Bozilenko and Dr. Debra Yu, who are joining Ascentage Pharma as independent non-executive

    11/24/24 7:27:00 PM ET
    $LIAN
    $MGTX
    $OLMA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $TLPH
    Financials

    Live finance-specific insights

    View All

    Talphera Announces Second Quarter 2025 Financial Results and Provides Corporate Update

    New sites accelerate registrational study enrollment - 15 patients have been enrolled in the NEPHRO study which remains on track with completion projected by the end of the year Cash and cash equivalents at June 30, 2025 were $6.8 million Conference call and webcast to be held Thursday, August 14, 2025 at 4:30 pm ET SAN MATEO, Calif., Aug. 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced second quarter 2025 financial results and provided a corporate update. "We have enrolled 15 patients in the NEPHRO clinical

    8/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera to Host Second Quarter Financial Results and Corporate Update Call and Webcast on Thursday, August 14, 2025

    SAN MATEO, Calif., Aug. 7, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release second quarter 2025 financial results after market close on Thursday, August 14, 2025, then host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss the results and provide an update on the Company's business. Webcast Information The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link

    8/7/25 4:35:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Talphera Announces First Quarter 2025 Financial Results and Provides Corporate Update

    Cash and investments at March 31, 2025, as adjusted to include the proceeds from the first tranche of the private placement financing which closed on April 2, 2025, were $9.8 million Three new clinical study sites activated and screening patients thus far in 2025, with five additional sites expected by mid-year, for a total of 13 Conference call and webcast to be held Wednesday, May 14, 2025 at 4:30 pm ET SAN MATEO, Calif., May 14, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2025 financial res

    5/14/25 4:05:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care